Blake Richards grew up in Manhattan and thought he would follow his father’s footsteps into finance. But when a job interviewer tried to pin him down on why he wanted to be in that field, he realized it wasn’t really for him. Instead he pursued technology, and more specifically in healthcare.
After spending time at Epic and Deloitte he became CEO of Elucid, a noninvasive cardiac imaging company that competes against HeartFlow, but goes beyond by quantifying plaque based on histopathology. It’s an FDA-cleared tool that helps avoid invasive cath lab procedures and helps physician identify patients who need more aggressive treatments.
December 23, 2021